Lipidated INTERLEUKIN-22

1 paper4 findings

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

On aging: the drug’s trials ARN judged to be about aging, of every trial that tests it for any use.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

1 lab

Animals1

Outcomes

Fecal energy loss

upin mice1

1 study

Lipidated INTERLEUKIN-22 increases fecal energy loss in mice (doubled).
“doubled fecal energy loss through reduced intestinal calorie absorption.”
Animals
Lipidated interleukin-22 reduces body weight and spares lean mass in mice by a novel gut-acting mechanism additive to GLP-1 agonism
Molecular therapy : the journal of the American Society of Gene Therapy27 Feb 2026

Insulin sensitivity

upin mice1

1 study

Lipidated INTERLEUKIN-22 improves insulin sensitivity in mice.
“Glycemic control was also enhanced, with lipidated IL-22 normalizing blood glucose, and improving insulin sensitivity independent of food intake.”
Animals
Lipidated interleukin-22 reduces body weight and spares lean mass in mice by a novel gut-acting mechanism additive to GLP-1 agonism
Molecular therapy : the journal of the American Society of Gene Therapy27 Feb 2026

Lean body mass

upin mice1

1 study

Lipidated INTERLEUKIN-22 improves lean body mass in mice (less than half the lean mass loss of GLP-1RAs or caloric restriction).
“Lipidated IL-22 preserved lean body mass with less than half the lean mass loss of GLP-1RAs or caloric restriction.”
Animals
Lipidated interleukin-22 reduces body weight and spares lean mass in mice by a novel gut-acting mechanism additive to GLP-1 agonism
Molecular therapy : the journal of the American Society of Gene Therapy27 Feb 2026

Body weight

downin mice1−20%

1 study

Lipidated INTERLEUKIN-22 decreases body weight in mice (up to 20%).
“Lipidated IL-22 induced up to 20% weight reduction as a monotherapy”
Animals
Lipidated interleukin-22 reduces body weight and spares lean mass in mice by a novel gut-acting mechanism additive to GLP-1 agonism
Molecular therapy : the journal of the American Society of Gene Therapy27 Feb 2026

Latest

1 in 12 months

Molecular Therapy1 Mar